NASDAQ:QNTM

Quantum Biopharma Q3 2026 Earnings Results & Report

Quantum Biopharma logo
$1.43 -0.09 (-5.66%)
As of 02:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Quantum Biopharma beat analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.06 versus the -$0.50 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes

Quantum Biopharma EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.44
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 8 quarters

Quantum Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Quantum Biopharma Q3 2026 Earnings FAQ

Quantum Biopharma (NASDAQ:QNTM) reported earnings of -$0.06 per share for Q3 2026, beating the consensus estimate of -$0.50. The report was announced on Thursday, November 12, 2026.

Quantum Biopharma Earnings Headlines

Quantum Biopharma (NASDAQ:QNTM) Upgraded at Wall Street Zen
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Quantum Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email.

About Quantum Biopharma

Quantum Biopharma (NASDAQ:QNTM) is a Canadian biopharmaceutical company focused on developing treatments for neurodegenerative and other challenging medical conditions. The company was formerly known as FSD Pharma and adopted its current name in 2024.

Its lead research program is Lucid-MS, an investigational drug candidate being developed for multiple sclerosis. The company describes the program as targeting myelin degradation, a process associated with the disease. Lucid-MS is still under development and is not an approved treatment.

Quantum BioPharma conducts its drug-development work through subsidiaries, including Lucid Psycheceuticals. Its activities are centered on research and development rather than marketing an established portfolio of approved medicines.

View Quantum Biopharma Profile